Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2020

In 2020, Anika Therapeutics Inc.'s disclosed short interest ran from 16.59% of shares outstanding on 15 Jan 2020 to 11.48% on 31 Dec 2020, a change of -5.11 percentage points. The year's high was 19.33% on 14 Feb 2020 and its low 11.48% on 31 Dec 2020, averaging 14.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.39 days on 31 Aug 2020. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2020

2020 in figures

Start of year
16.59% (15 Jan 2020)
End of year
11.48% (31 Dec 2020)
Change
-5.11 pp
High
19.33% (14 Feb 2020)
Low
11.48% (31 Dec 2020)
Average
14.10%
Highest days to cover
29.39 (31 Aug 2020)
SEC filings marked
8

Every report in 2020

Anika Therapeutics Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202016.59%15.23
31 Jan 202019.20%13.74
14 Feb 202019.33%20.34
28 Feb 202016.81%8.86results (8-K)
13 Mar 202013.25%8.7310-K filed
31 Mar 202012.59%8.00
15 Apr 202012.59%13.67
30 Apr 202012.64%14.76
15 May 202013.19%9.69results (8-K)
29 May 202014.47%13.3210-Q filed
15 Jun 202015.11%14.23
30 Jun 202014.89%18.44
15 Jul 202014.64%19.83
31 Jul 202014.23%22.57results (8-K)
14 Aug 202014.33%19.4810-Q filed
31 Aug 202014.31%29.39
15 Sep 202014.41%23.67
30 Sep 202012.72%12.68
15 Oct 202012.35%19.88
30 Oct 202012.76%23.47
13 Nov 202012.50%16.57results (8-K), 10-Q filed
30 Nov 202012.15%28.79
15 Dec 202011.90%22.65
31 Dec 202011.48%11.28

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.